Miłosz Jamroży
CEO
This startup develops a medical device that measures multiple heart parameters and transmits the data to a web platform for algorithmic analysis. This system enables rapid assessment of heart conditions, helping patients and physicians accelerate cardiovascular disease diagnosis.
Funding not disclosed


CEO
Diagnosing the cause of dyspnea (shortness of breath) is challenging, often requiring multiple tests and specialist visits over several weeks to differentiate between Chronic Heart Failure (CHF) and Chronic Obstructive Pulmonary Disease (COPD). Initial misdiagnosis rates can be as high as 68%, leading to delayed treatment and potentially adverse health outcomes.
Mudisocard is a telemedical system designed for rapid and accurate diagnosis of heart conditions, particularly in patients presenting with dyspnea. The system records 3D ECG, 3D impedance, and chest auscultation signals simultaneously using a set of electrodes. These signals are transmitted to a cloud-based platform where proprietary algorithms analyze the dynamic patterns of each heartbeat, comparing them to previous ones. This analysis enables clinicians to quickly distinguish between CHF and COPD, facilitating prompt and appropriate treatment decisions during a single patient visit.
The primary target audience includes healthcare professionals such as primary care physicians and cardiologists seeking a faster, more accurate method for diagnosing the cause of dyspnea, as well as hospitals and clinics aiming to reduce diagnostic costs and improve patient outcomes.